Recent Advancement in mRNA Vaccine Development and Applications

被引:38
作者
Al Fayez, Nojoud [1 ]
Nassar, Majed S. [1 ]
Alshehri, Abdullah A. [1 ]
Alnefaie, Meshal K. [1 ]
Almughem, Fahad A. [1 ]
Alshehri, Bayan Y. [1 ]
Alawad, Abdullah O. [2 ]
Tawfik, Essam A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol KACST, Adv Diag & Therapeut Inst, Hlth Sect, Riyadh 11442, Saudi Arabia
[2] King Abdulaziz City Sci & Technol KACST, Hlth Aging Res Inst, Hlth Sect, Riyadh 11442, Saudi Arabia
关键词
mRNA vaccine; delivery; lipid nanoparticles (LNPs); infectious diseases; cancer; immune response; PHASE-I TRIAL; COVID-19; VACCINES; CIRCULAR RNAS; CAP-ANALOGS; DELIVERY; NANOPARTICLES; THERAPEUTICS; TRANSLATION; MECHANISMS; PROTECTION;
D O I
10.3390/pharmaceutics15071972
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Messenger RNA (mRNA) vaccine development for preventive and therapeutic applications has evolved rapidly over the last decade. The mRVNA vaccine has proven therapeutic efficacy in various applications, including infectious disease, immunotherapy, genetic disorders, regenerative medicine, and cancer. Many mRNA vaccines have made it to clinical trials, and a couple have obtained FDA approval. This emerging therapeutic approach has several advantages over conventional methods: safety; efficacy; adaptability; bulk production; and cost-effectiveness. However, it is worth mentioning that the delivery to the target site and in vivo degradation and thermal stability are boundaries that can alter their efficacy and outcomes. In this review, we shed light on different types of mRNA vaccines, their mode of action, and the process to optimize their development and overcome their limitations. We also have explored various delivery systems focusing on the nanoparticle-mediated delivery of the mRNA vaccine. Generally, the delivery system plays a vital role in enhancing mRNA vaccine stability, biocompatibility, and homing to the desired cells and tissues. In addition to their function as a delivery vehicle, they serve as a compartment that shields and protects the mRNA molecules against physical, chemical, and biological activities that can alter their efficiency. Finally, we focused on the future considerations that should be attained for safer and more efficient mRNA application underlining the advantages and disadvantages of the current mRNA vaccines.
引用
收藏
页数:24
相关论文
共 177 条
  • [1] [Anonymous], FUSOGENIX DRUG DELIV
  • [2] [Anonymous], 2020, Immunization Agenda 2030: A Global Strategy to Leave No One Behind'
  • [3] [Anonymous], FINANCIALS SEC FILIN
  • [4] [Anonymous], MODERNA REPORTS 2 QU
  • [5] [Anonymous], SEC FILING BIONTECH
  • [6] [Anonymous], CORONAVIRUS DIS COVI
  • [7] A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
    Arevalo, Claudia P.
    Bolton, Marcus J.
    Le Sage, Valerie
    Ye, Naiqing
    Furey, Colleen
    Muramatsu, Hiromi
    Alameh, Mohamad-Gabriel
    Pardi, Norbert
    Drapeau, Elizabeth M.
    Parkhouse, Kaela
    Garretson, Tyler
    Morris, Jeffrey S.
    Moncla, Louise H.
    Tam, Ying K.
    Fan, Steven H. Y.
    Lakdawala, Seema S.
    Weissman, Drew
    Hensley, Scott E.
    [J]. SCIENCE, 2022, 378 (6622) : 899 - 904
  • [8] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [9] The clinical progress of mRNA vaccines and immunotherapies
    Barbier, Ann J.
    Jiang, Allen Yujie
    Zhang, Peng
    Wooster, Richard
    Anderson, Daniel G.
    [J]. NATURE BIOTECHNOLOGY, 2022, 40 (06) : 840 - 854
  • [10] Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
    Barda, Noam
    Dagan, Noa
    Ben-Shlomo, Yatir
    Kepten, Eldad
    Waxman, Jacob
    Ohana, Reut
    Hernan, Miguel A.
    Lipsitch, Marc
    Kohane, Isaac
    Netzer, Doron
    Reis, Ben Y.
    Balicer, Ran D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) : 1078 - 1090